JPS6231691B2 - - Google Patents
Info
- Publication number
- JPS6231691B2 JPS6231691B2 JP51033960A JP3396076A JPS6231691B2 JP S6231691 B2 JPS6231691 B2 JP S6231691B2 JP 51033960 A JP51033960 A JP 51033960A JP 3396076 A JP3396076 A JP 3396076A JP S6231691 B2 JPS6231691 B2 JP S6231691B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- drug
- filter medium
- present
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000006454 hepatitis Diseases 0.000 claims description 36
- 231100000283 hepatitis Toxicity 0.000 claims description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000002244 precipitate Substances 0.000 claims description 14
- 210000002700 urine Anatomy 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- -1 Alternatively Chemical compound 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 description 29
- 229940079593 drug Drugs 0.000 description 27
- 238000000034 method Methods 0.000 description 11
- 230000003908 liver function Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 238000009535 clinical urine test Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000003708 ampul Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- UNKYOXKQMHLGPW-UHFFFAOYSA-N Urobilin IXalpha Natural products CCC1=C(C)C(=O)NC1CC2=NC(=Cc3[nH]c(CC4NC(=O)C(=C4C)CC)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O UNKYOXKQMHLGPW-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- KDCCOOGTVSRCHX-UHFFFAOYSA-N urobilin Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(CC3C(=C(CC)C(=O)N3)C)=N2)CCC(O)=O)N1 KDCCOOGTVSRCHX-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3396076A JPS52117417A (en) | 1976-03-27 | 1976-03-27 | Production of medicine used in hepatisis treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3396076A JPS52117417A (en) | 1976-03-27 | 1976-03-27 | Production of medicine used in hepatisis treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS52117417A JPS52117417A (en) | 1977-10-01 |
| JPS6231691B2 true JPS6231691B2 (en]) | 1987-07-09 |
Family
ID=12401047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3396076A Granted JPS52117417A (en) | 1976-03-27 | 1976-03-27 | Production of medicine used in hepatisis treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS52117417A (en]) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03128106U (en]) * | 1990-04-10 | 1991-12-24 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01294637A (ja) * | 1988-05-24 | 1989-11-28 | Tetsuo Takano | 免疫抗体、補体の採取法と採取装置 |
-
1976
- 1976-03-27 JP JP3396076A patent/JPS52117417A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03128106U (en]) * | 1990-04-10 | 1991-12-24 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS52117417A (en) | 1977-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trolle | Decrease of total serum-bilirubin concentration in newborn infants after phenobarbitone treatment | |
| CN102641298B (zh) | 一种预防和治疗肿瘤的效应细胞组合及其制备方法 | |
| JPH0378850B2 (en]) | ||
| Powell et al. | Reye's syndrome: isolation of parainfluenza virus: report of three cases | |
| CN104188900B (zh) | 一种茯苓多糖注射剂及其制备方法 | |
| King et al. | An intravenous galactose-tolerance test | |
| WO2017146230A1 (ja) | 試験方法 | |
| JPS6231691B2 (en]) | ||
| CN107982530A (zh) | Semaphrin7A抗体在制备用于治疗心肌炎疾病的药物中的应用及其药物 | |
| Goldenberg et al. | Cardiac tamponade in juvenile chronic arthritis: report of two cases and review of publications. | |
| Macdougall | Intraperitoneal blood transfusions in children | |
| Lepore et al. | Fulminant hepatitis with coma successfully treated by plasmapheresis and hyperimmune Australia-Antibody-rich plasma. | |
| McLean et al. | Direct exchange blood transfusion in treatment of hepatic coma | |
| OVASSAPIAN | Effects of administration of atropine and neostigmine in man | |
| Zaman et al. | Effect of intravenous iron therapy on serum ferritin and haemogobin levels in children reporting with iron defeciency anaemia | |
| US6395717B1 (en) | Therapeutic drug for endotoxin blood symptom and multi-organ failure induced thereby | |
| Soule et al. | Herbicola lathyri septicemia, myoglobinuria, and acute renal failure | |
| Sevick et al. | Long-term management of arrhythmogenic right ventricular dysplasia | |
| Talbot | Sarcoid myopathy | |
| O'Brien et al. | Alcoholic myopathy | |
| Fülöp et al. | Fatal anaphylactic shock in a patient undergoing hemodialysis via a polyurethane catheter | |
| WO1983004260A1 (en) | Human leukocyte pepsin-like enzyme, and a therapeutic agent containing said enzyme as effective ingredient for treating allergic disorder, immune complex disease, and tumor | |
| Bolfer et al. | 1132: use of single pass lipid dialysis for the treatment of avermectin toxicity | |
| Utting et al. | Haemolytic-uraemic syndrome in an adult with pericarditis and pleurisy | |
| JPH03240738A (ja) | 糖尿病性壊疽治療剤 |